ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation [Anatol J Cardiol]
Anatol J Cardiol. 2020; 23(1): 10-18 | DOI: 10.14744/AnatolJCardiol.2019.30766

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation

Anetta Undas, Leszek Drabik
John Paul II Hospital, Krakow, Poland

Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease. However, their use in cancer patients increases and real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and the current expert opinions on this subject have been summarized in this review article.

Keywords: anticoagulation, atrial fibrillation, bleeding, cancer, direct oral anticoagulants

Anetta Undas, Leszek Drabik. Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation. Anatol J Cardiol. 2020; 23(1): 10-18

Corresponding Author: Anetta Undas, Poland
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.